PAX5 and precursor B-cell acute lymphoblastic leukemia: Hence, these expression data provided a molecular explanation why B220 downregulation can be used as a surrogate marker for Pax5Jak2/+ B‐ALL tumors, and furthermore indicated that the function of wild‐type Pax5 may be impaired in Pax5Jak2/+ B‐ALL tumors.